Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Status:
Terminated
Trial end date:
2019-04-10
Target enrollment:
Participant gender:
Summary
Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with
2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in
Lynch Syndrome patients for 2 years.
Phase:
Phase 2
Details
Lead Sponsor:
Christoph Gasche Rabin Medical Center
Collaborators:
Ann-Sofie Backman, MD PhD, Sweden Prof. Dr. Gabriela Möslein, Germany Prof. Dr. Hans Vasen, The Netherlands Prof. Dr. med. Jan Lubinski, Poland Prof. Dr. med. Yaron Niv, Israel Univ. Prof. Dr. Judith Karner-Hanusch, Austria